<DOC>
	<DOCNO>NCT00757172</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , panitumumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Drugs use chemotherapy , cisplatin docetaxel , work different way kill tumor cell stop grow . Radiation therapy use high-energy x-ray kill tumor cell . Giving combination chemotherapy together panitumumab radiation therapy surgery may make tumor small reduce amount normal tissue need remove . PURPOSE : This phase II trial study well give panitumumab together docetaxel , cisplatin , radiation therapy , surgery work treat patient newly diagnose , locally advanced esophageal cancer cancer gastroesophageal junction .</brief_summary>
	<brief_title>Panitumumab , Docetaxel , Cisplatin , Radiation Therapy , Surgery Treating Patients With Newly Diagnosed , Locally Advanced Esophageal Cancer Cancer Gastroesophageal Junction</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine pathologic complete response rate patient newly diagnose , locally advanced adenocarcinoma distal esophagus gastroesophageal junction treat neoadjuvant panitumumab combination chemoradiotherapy follow surgery . Secondary - To determine near-complete pathologic response rate primary tumor ( ≤ 10 % residual viable cancer ) . - To determine overall survival disease-free survival rate patient . - To determine safety profile regimen . OUTLINE : Patients receive panitumumab IV 1 hour , docetaxel IV 1 hour , cisplatin IV 1-2 hour day 1 week 1 , 3 , 5 , 7 , 9 . Patients also undergo radiotherapy daily 5 day week begin week 5 continue 5.5 week . Treatment continue absence disease progression unacceptable toxicity . Beginning 6-9 week completion chemoradiotherapy , patient evidence metastatic disease undergo esophagectomy . After completion study treatment , patient follow every 3 month 2 year every 6 month 1 year OR every 6 month 3 year .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . ≥ 18 year old 2 . ECOG/Zubrod Performance Status 01 3 . Biopsyproven resectable primary ( nonrecurrent ) adenocarcinoma distal esophagus GE junction ( Siewert Type I II ) Siewert Type I : adenocarcinoma distal esophagus Siewert Type II : adenocarcinoma esophagogastric junction/real cardia 4 . Preregistration EUS , CT chest upper abdomen , PET must support clinical stage T3N0M0 , T23N1M0 T23N01M1a ( celiac adenopathy must ≤ 2 cm EUS ) . Clinically stag T1 tumor T2N0M0 tumor eligible . N1 require biopsy/FNA . Note : Patients require stent nutrition must stag examination scan complete stent placement . 5 . No definitive radiological evidence distant metastasis . 6 . No preexist grade 2 great peripheral neuropathy ( CTCAE v3 ) etiology . 7 . Adequate bone marrow , hepatic renal function prior registration : WBC ≥ 3,000/mm³ ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9.5 g/dL Creatinine ≤ 1.5 mg/dL Total bilirubin ≤ 3 mg/dL AST ( SGOT ) ≤ 2.0 time upper limit normal ( ULN ) ALT ( SGPT ) ≤ 2.0 time ULN Alkaline phosphatase ≤ 2.0 time ULN Albumin ≥ 2.0 g/dL OR prealbumin ≥ 15 mg/dL Magnesium ≥ low limit normal ( LLN ) 8 . Patient must evaluate registration medical oncologist , radiation oncologist surgeon deem fit protocol therapy surgery . 9 . No prior invasive malignancy , unless diseasefree ≥ 5 year prior registration ( Exceptions : nonmelanoma skin cancer , insitu cancer ) . 10 . Nonpregnant nonbreast feeding . Female participant childbearing potential must negative urine serum pregnancy test prior registration . Perimenopausal participant must amenorrheic ≥ 12 month consider childbearing potential . All patient reproductive potential must agree use effective method birthcontrol receive study therapy six month completion therapy . 11 . No prior chest upper abdomen radiotherapy ; prior therapy cisplatin , docetaxel , panitumumab antiEGFR therapy prior esophageal gastric surgery ( Exception : prior surgery treat reflux disease ) 12 . No uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psyschiatric illness/social situation would limit compliance study requirement . 13 . No history interstitial lung disease ( eg , pneumonitis pulmonary fibrosis evidence interstitial lung disease baseline chest CT scan 14 . No history medical psychiatric condition laboratory abnormality opinion investigator may increase risk associate study participation investigational product ( ) administration may interfere interpretation result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>adenocarcinoma gastroesophageal junction</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
</DOC>